...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical drug investigation >Implications of the European Organisation for Research And Treatment Of Cancer (EORTC) Guidelines on the Use of Granulocyte Colony-Stimulating Factor (G-CSF) for Lymphoma Care
【24h】

Implications of the European Organisation for Research And Treatment Of Cancer (EORTC) Guidelines on the Use of Granulocyte Colony-Stimulating Factor (G-CSF) for Lymphoma Care

机译：欧洲癌症研究与治疗组织（EORTC）准则对粒细胞集落刺激因子（G-CSF）在淋巴瘤治疗中的应用

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Febrile neutropenia (FN) is a potentially life-threatening complication of myelosuppressive chemotherapy. The European Organisation for Research and Treatment of Cancer (EORTC) guidelines recommend use of primary granulocyte colony-stimulating factor (G-CSF) prophylaxis if the overall FN risk to a patient is >=20%, or if a reduction in chemotherapy dose intensity correlates with a poorer outcome. Many of the regimens used for treatment of lymphoma, including R-CHOP (rituximab combined with cyclophos-phamide, doxorubicin, vincristine and prednisolone), are associated with an FN risk of approximately 20% or higher. Individual patient factors that may increase the risk of FN such as advanced age or advanced disease should be taken into account when assessing the need for G-CSF support. Predictive models are being developed to facilitate individual risk assessment. Additional anti-infective prophylaxis may be indicated in some settings.
机译：高热性中性粒细胞减少症（FN）是骨髓抑制性化疗可能威胁生命的并发症。欧洲癌症研究与治疗组织（EORTC）指南建议，如果患者的总FN风险大于等于20％或降低化疗剂量强度，则应使用初级粒细胞集落刺激因子（G-CSF）进行预防与较差的结果相关。用于治疗淋巴瘤的许多方案，包括R-CHOP（利妥昔单抗联合环磷酰胺，阿霉素，长春新碱和泼尼松龙），与FN风险约20％或更高有关。在评估是否需要G-CSF支持时，应考虑可能增加FN风险的个体患者因素，例如老年或晚期疾病。正在开发预测模型以促进个人风险评估。在某些情况下可能需要进行其他抗感染预防措施。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号